γ‐Herpesviruses and cellular signaling in AIDS‐associated malignancies

γ‐Herpesviruses, Epstein–Barr virus (EBV/HHV‐4) and Kaposi's sarcoma‐associated herpesvirus (KSHV/HHV‐8), are involved in human carcinogenesis, particularly in immunocompromised patients. Virus‐associated malignancies are becoming of significant concern for the mortality of long‐lived immunocompromised patients, and therefore, research of advanced strategies for AIDS‐related malignancies is an important field in cancer chemotherapy. Detailed understanding of the EBV and KSHV lifecycle and related cancers at the molecular level is required for novel strategies of molecular‐targeted cancer chemotherapy. The present review gives a simple outline of the functional interactions between KSHV‐ and EBV‐viral gene products and host cell deregulated signaling pathways as possible targets of chemotherapy against AIDS‐related malignancies. (Cancer Sci 2007; 98: 1288–1296)

[1]  S. Verma,et al.  The Minimal Replicator Element of the Kaposi's Sarcoma-Associated Herpesvirus Terminal Repeat Supports Replication in a Semiconservative and Cell-Cycle-Dependent Manner , 2006, Journal of Virology.

[2]  M. DePamphilis,et al.  The BAH domain facilitates the ability of human Orc1 protein to activate replication origins in vivo , 2006, The EMBO journal.

[3]  Y. Takebe,et al.  Ets-1-dependent Expression of Vascular Endothelial Growth Factor Receptors Is Activated by Latency-associated Nuclear Antigen of Kaposi's Sarcoma-associated Herpesvirus through Interaction with Daxx* , 2006, Journal of Biological Chemistry.

[4]  T. Kanda,et al.  EB virus‐encoded RNAs are recognized by RIG‐I and activate signaling to induce type I IFN , 2006, The EMBO journal.

[5]  C. Gélinas,et al.  Epstein-Barr Virus Nuclear Antigen 2 trans-Activates the Cellular Antiapoptotic bfl-1 Gene by a CBF1/RBPJκ-Dependent Pathway , 2006, Journal of Virology.

[6]  E. Sausville,et al.  The TSC2/mTOR pathway drives endothelial cell transformation induced by the Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor. , 2006, Cancer cell.

[7]  E. Robertson,et al.  Intracellular-activated Notch1 can reactivate Kaposi's sarcoma-associated herpesvirus from latency. , 2006, Virology.

[8]  L. Lanier.  Viral immunoreceptor tyrosine-based activation motif (ITAM)-mediated signaling in cell transformation and cancer. , 2006, Trends in cell biology.

[9]  Cun-Yu Wang,et al.  Notch signaling in the regulation of tumor angiogenesis. , 2006, Trends in cell biology.

[10]  Ling Wang,et al.  Immortalization of primary endothelial cells by the K1 protein of Kaposi's sarcoma-associated herpesvirus. , 2006, Cancer research.

[11]  T. Kowalik,et al.  Inhibition of the ATM/p53 Signal Transduction Pathway by Kaposi's Sarcoma-Associated Herpesvirus Interferon Regulatory Factor 1 , 2006, Journal of Virology.

[12]  S. Verma,et al.  Latency-Associated Nuclear Antigen (LANA) of Kaposi's Sarcoma-Associated Herpesvirus Interacts with Origin Recognition Complexes at the LANA Binding Sequence within the Terminal Repeats , 2006, Journal of Virology.

[13]  G. Peters,et al.  Phosphorylation of the Cyclin-Dependent Kinase Inhibitor p21Cip1 on Serine 130 Is Essential for Viral Cyclin-Mediated Bypass of a p21Cip1-Imposed G1 Arrest , 2006, Molecular and Cellular Biology.

[14]  D. Dittmer,et al.  The latency-associated nuclear antigen of Kaposi sarcoma-associated herpesvirus induces B cell hyperplasia and lymphoma. , 2006, The Journal of clinical investigation.

[15]  K. Luger,et al.  The Nucleosomal Surface as a Docking Station for Kaposi's Sarcoma Herpesvirus LANA , 2006, Science.

[16]  P. Ojala,et al.  KSHV viral cyclin inactivates p27KIP1 through Ser10 and Thr187 phosphorylation in proliferating primary effusion lymphomas. , 2006, Blood.

[17]  J. Pagano,et al.  Up-regulation of β-catenin by a viral oncogene correlates with inhibition of the seven in absentia homolog 1 in B lymphoma cells , 2005 .

[18]  N. Raab-Traub,et al.  Epstein–Barr virus latent membrane protein 1 CTAR1 mediates rodent and human fibroblast transformation through activation of PI3K , 2005, Oncogene.

[19]  M. Fujimuro,et al.  Regulation of the Interaction between Glycogen Synthase Kinase 3 and the Kaposi's Sarcoma-Associated Herpesvirus Latency-Associated Nuclear Antigen , 2005, Journal of Virology.

[20]  S. Verma,et al.  Induction of Kaposi's Sarcoma-Associated Herpesvirus Latency-Associated Nuclear Antigen by the Lytic Transactivator RTA: a Novel Mechanism for Establishment of Latency , 2005, Journal of Virology.

[21]  J. Pietenpol,et al.  Constitutively active K-cyclin/cdk6 kinase in Kaposi sarcoma-associated herpesvirus-infected cells. , 2005, Journal of the National Cancer Institute.

[22]  L. Young,et al.  Modulation of the Cell Growth Regulator mTOR by Epstein-Barr Virus-Encoded LMP2A , 2005, Journal of Virology.

[23]  C. Arrowsmith,et al.  Structure of the p53 binding domain of HAUSP/USP7 bound to Epstein-Barr nuclear antigen 1 implications for EBV-mediated immortalization. , 2005, Molecular cell.

[24]  E. Robertson,et al.  Kaposi's Sarcoma-Associated Herpesvirus Reactivation Is Regulated by Interaction of Latency-Associated Nuclear Antigen with Recombination Signal Sequence-Binding Protein Jκ, the Major Downstream Effector of the Notch Signaling Pathway , 2005, Journal of Virology.

[25]  Jianhong Hu,et al.  Characterization of the Minimal Replicator of Kaposi's Sarcoma-Associated Herpesvirus Latent Origin , 2005, Journal of Virology.

[26]  B. Sugden,et al.  Origins of bidirectional replication of Epstein–Barr virus: Models for understanding mammalian origins of DNA synthesis , 2005, Journal of cellular biochemistry.

[27]  M. Rosenkilde,et al.  Epstein-Barr Virus-Encoded BILF1 Is a Constitutively Active G Protein-Coupled Receptor , 2005, Journal of Virology.

[28]  William Stedman,et al.  ORC, MCM, and Histone Hyperacetylation at the Kaposi's Sarcoma-Associated Herpesvirus Latent Replication Origin , 2004, Journal of Virology.

[29]  K. Yamanishi,et al.  Poly(ADP-Ribose) Polymerase 1 Binds to Kaposi's Sarcoma-Associated Herpesvirus (KSHV) Terminal Repeat Sequence and Modulates KSHV Replication in Latency , 2004, Journal of Virology.

[30]  G. Tosato,et al.  HIV-1 Tat enhances Kaposi sarcoma-associated herpesvirus (KSHV) infectivity. , 2004, Blood.

[31]  B. Damania.  Oncogenic γ-herpesviruses: comparison of viral proteins involved in tumorigenesis , 2004, Nature Reviews Microbiology.

[32]  K. Kinzler,et al.  Cancer genes and the pathways they control , 2004, Nature Medicine.

[33]  S. Verma,et al.  Kaposi's Sarcoma-Associated Herpesvirus-Encoded Latency-Associated Nuclear Antigen Inhibits Lytic Replication by Targeting Rta: a Potential Mechanism for Virus-Mediated Control of Latency , 2004, Journal of Virology.

[34]  N. Jones,et al.  The cell cycle and how it is steered by Kaposi's sarcoma-associated herpesvirus cyclin. , 2004, The Journal of general virology.

[35]  Muyang Li,et al.  A dynamic role of HAUSP in the p53-Mdm2 pathway. , 2004, Molecular cell.

[36]  M. Ballestas,et al.  KSHV LANA1 binds DNA as an oligomer and residues N-terminal to the oligomerization domain are essential for DNA binding, replication, and episome persistence. , 2004, Virology.

[37]  H. Heslop,et al.  Evidence for the Presentation of Major Histocompatibility Complex Class I–restricted Epstein-Barr Virus Nuclear Antigen 1 Peptides to CD8+ T Lymphocytes , 2004, The Journal of experimental medicine.

[38]  B. Damania,et al.  The K1 Protein of Kaposi's Sarcoma-Associated Herpesvirus Activates the Akt Signaling Pathway , 2004, Journal of Virology.

[39]  M. Fujimuro,et al.  Manipulation of glycogen-synthase kinase-3 activity in KSHV-associated cancers , 2004, Journal of Molecular Medicine.

[40]  N. Raab-Traub,et al.  Epstein-Barr Virus Latent Membrane Protein 2A Activates β-Catenin Signaling in Epithelial Cells , 2003, Journal of Virology.

[41]  K. Takada,et al.  Autocrine growth of Epstein-Barr virus-positive gastric carcinoma cells mediated by an Epstein-Barr virus-encoded small RNA. , 2003, Cancer research.

[42]  S. Howell,et al.  KSHV vFLIP binds to IKK-γ to activate IKK , 2003, Journal of Cell Science.

[43]  R. Fåhraeus,et al.  Self-Inhibition of Synthesis and Antigen Presentation by Epstein-Barr Virus-Encoded EBNA1 , 2003, Science.

[44]  L. Rainbow,et al.  Activation of Mitogen-Activated Protein Kinase and NF-κB Pathways by a Kaposi's Sarcoma-Associated Herpesvirus K15 Membrane Protein , 2003, Journal of Virology.

[45]  M. Fujimuro,et al.  The Latency-Associated Nuclear Antigen of Kaposi's Sarcoma-Associated Herpesvirus Manipulates the Activity of Glycogen Synthase Kinase-3β , 2003, Journal of Virology.

[46]  R. Sun,et al.  Kaposi's sarcoma-associated herpesvirus encoded vFLIP induces cellular IL-6 expression: the role of the NF-κB and JNK/AP1 pathways , 2003, Oncogene.

[47]  M. Reitz,et al.  Human Herpesvirus 8-Encoded vGPCR Activates Nuclear Factor of Activated T Cells and Collaborates with Human Immunodeficiency Virus Type 1 Tat , 2003, Journal of Virology.

[48]  Akira Kikuchi,et al.  Tumor formation by genetic mutations in the components of the Wnt signaling pathway , 2003, Cancer science.

[49]  Frederick Y. Wu,et al.  A novel viral mechanism for dysregulation of β-catenin in Kaposi's sarcoma–associated herpesvirus latency , 2003, Nature Medicine.

[50]  S. Rafii,et al.  Kaposi's sarcoma associated herpesvirus G protein-coupled receptor immortalizes human endothelial cells by activation of the VEGF receptor-2/ KDR. , 2003, Cancer cell.

[51]  E. Cesarman,et al.  The Kaposi's Sarcoma-Associated Herpesvirus G Protein-Coupled Receptor Has Broad Signaling Effects in Primary Effusion Lymphoma Cells , 2003, Journal of Virology.

[52]  Takashi Tsuruo,et al.  Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal , 2003, Cancer science.

[53]  Jianhong Hu,et al.  The Latency-Associated Nuclear Antigen of Kaposi's Sarcoma-Associated Herpesvirus Supports Latent DNA Replication in Dividing Cells , 2002, Journal of Virology.

[54]  C. Lim,et al.  Functional Dissection of Latency-Associated Nuclear Antigen 1 of Kaposi's Sarcoma-Associated Herpesvirus Involved in Latent DNA Replication and Transcription of Terminal Repeats of the Viral Genome , 2002, Journal of Virology.

[55]  E. White,et al.  Viral homologs of BCL-2: role of apoptosis in the regulation of virus infection. , 2002, Genes & development.

[56]  Ching‐Hwa Tsai,et al.  Epstein-Barr Virus Latent Membrane Protein 2A Regulates c-Jun Protein through Extracellular Signal-Regulated Kinase , 2002, Journal of Virology.

[57]  D. Ganem,et al.  The lytic switch protein of KSHV activates gene expression via functional interaction with RBP-Jkappa (CSL), the target of the Notch signaling pathway. , 2002, Genes & development.

[58]  Tyson V. Sharp,et al.  Characterization of an anti‐apoptotic glycoprotein encoded by Kaposi's sarcoma‐associated herpesvirus which resembles a spliced variant of human survivin , 2002, The EMBO journal.

[59]  M. Eby,et al.  The Human Herpes Virus 8-encoded Viral FLICE Inhibitory Protein Physically Associates with and Persistently Activates the IκB Kinase Complex* , 2002, The Journal of Biological Chemistry.

[60]  P. Lieberman,et al.  Telomeric proteins regulate episomal maintenance of Epstein-Barr virus origin of plasmid replication. , 2002, Molecular cell.

[61]  T. Mäkelä,et al.  CAK-independent activation of CDK6 by a viral cyclin. , 2001, Molecular biology of the cell.

[62]  J. Yates,et al.  Replication from oriP of Epstein-Barr Virus Requires Exact Spacing of Two Bound Dimers of EBNA1 Which Bend DNA , 2001, Journal of Virology.

[63]  D. Thorley-Lawson,et al.  Epstein-Barr virus: exploiting the immune system , 2001, Nature Reviews Immunology.

[64]  E. Kremmer,et al.  Human origin recognition complex binds to the region of the latent origin of DNA replication of Epstein–Barr virus , 2001, The EMBO journal.

[65]  Anindya Dutta,et al.  Replication from oriP of Epstein-Barr Virus Requires Human ORC and Is Inhibited by Geminin , 2001, Cell.

[66]  T. Yoshizaki,et al.  Induction of cyclooxygenase-2 by Epstein–Barr virus latent membrane protein 1 is involved in vascular endothelial growth factor production in nasopharyngeal carcinoma cells , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[67]  J. Sample,et al.  Latent Membrane Protein 2A-Mediated Effects on the Phosphatidylinositol 3-Kinase/Akt Pathway , 2000, Journal of Virology.

[68]  C. Boshoff,et al.  The latent nuclear antigen of Kaposi sarcoma-associated herpesvirus targets the retinoblastoma–E2F pathway and with the oncogene Hras transforms primary rat cells , 2000, Nature Medicine.

[69]  S. Mori,et al.  Expression and localization of human herpesvirus 8-encoded proteins in primary effusion lymphoma, Kaposi's sarcoma, and multicentric Castleman's disease. , 2000, Virology.

[70]  G. Nabel,et al.  p53 inhibition by the LANA protein of KSHV protects against cell death , 1999, Nature.

[71]  S. Maruo,et al.  Oncogenic Role of Epstein-Barr Virus-Encoded RNAs in Burkitt’s Lymphoma Cell Line Akata , 1999, Journal of Virology.

[72]  A. Nel,et al.  Inflammatory cytokines synergize with the HIV-1 Tat protein to promote angiogenesis and Kaposi's sarcoma via induction of basic fibroblast growth factor and the alpha v beta 3 integrin. , 1999, Journal of immunology.

[73]  S. Mori,et al.  High expression of HHV-8-encoded ORF73 protein in spindle-shaped cells of Kaposi's sarcoma. , 1999, The American journal of pathology.

[74]  R. Majeti,et al.  Deregulated signal transduction by the K1 gene product of Kaposi's sarcoma-associated herpesvirus. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[75]  C. Boshoff,et al.  Transcriptional analysis of human herpesvirus-8 open reading frames 71, 72, 73, K14, and 74 in a primary effusion lymphoma cell line. , 1999, Virology.

[76]  C. Boshoff,et al.  Degradation of p27Kip cdk inhibitor triggered by Kaposi's sarcoma virus cyclin–cdk6 complex , 1999, The EMBO journal.

[77]  N. Jones,et al.  Modulation of p27Kip1 levels by the cyclin encoded by Kaposi's sarcoma‐associated herpesvirus , 1999 .

[78]  D. Ganem,et al.  Reactivation of Kaposi's sarcoma-associated herpesvirus infection from latency by expression of the ORF 50 transactivator, a homolog of the EBV R protein. , 1998, Virology.

[79]  D. Scadden.  AIDS-related malignancies. , 1998, Current opinion in oncology.

[80]  E. Kieff,et al.  Epstein–Barr virus-transforming protein latent infection membrane protein 1 activates transcription factor NF-κB through a pathway that includes the NF-κB-inducing kinase and the IκB kinases IKKα and IKKβ , 1998 .

[81]  N. Jones,et al.  Herpes viral cyclin/Cdk6 complexes evade inhibition by CDK inhibitor proteins , 1997, Nature.

[82]  E. Kieff,et al.  The Epstein–Barr virus oncogene product latent membrane protein 1 engages the tumor necrosis factor receptor-associated death domain protein to mediate B lymphocyte growth transformation and activate NF-κB , 1997 .

[83]  W. Kolch,et al.  Epstein–Barr virus latent membrane protein‐1 triggers AP‐1 activity via the c‐Jun N‐terminal kinase cascade , 1997, The EMBO journal.

[84]  J. Russo,et al.  Kaposi's sarcoma-associated herpesvirus encodes a functional Bcl-2 homologue , 1997, Nature Medicine.

[85]  F. Neipel,et al.  Kaposi's sarcoma-associated herpesvirus encodes a functional cyclin , 1997, Journal of virology.

[86]  R. Pfuetzner,et al.  Crystal Structure of the DNA-Binding Domain of the Epstein–Barr Virus Origin-Binding Protein, EBNA1, Bound to DNA , 1996, Cell.

[87]  C. Boshoff,et al.  Kaposi's sarcoma-associated herpesvirus infects endothelial and spindle cells , 1995, Nature Medicine.

[88]  F. Sigaux,et al.  Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. , 1995, Blood.

[89]  Stefan Imreh,et al.  Inhibition of antigen processing by the internal repeat region of the Epstein–Barr virus nuclear antigen-1 , 1995, Nature.

[90]  J. Hsieh,et al.  Masking of the CBF1/RBPJ kappa transcriptional repression domain by Epstein-Barr virus EBNA2. , 1995, Science.

[91]  C. Ware,et al.  The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family , 1995, Cell.

[92]  E. Cesarman,et al.  Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. , 1994, Science.

[93]  P. Ling,et al.  Mediation of Epstein-Barr virus EBNA2 transactivation by recombination signal-binding protein J kappa. , 1994, Science.

[94]  M. Rowe,et al.  Epstein-Barr virus-coded BHRF1 protein, a viral homologue of Bcl-2, protects human B cells from programmed cell death. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[95]  L. Frappier,et al.  Identification of EBNA1 amino acid sequences required for the interaction of the functional elements of the Epstein-Barr virus latent origin of DNA replication , 1993, Journal of virology.

[96]  D. Reisman,et al.  trans activation of an Epstein-Barr viral transcriptional enhancer by the Epstein-Barr viral nuclear antigen 1 , 1986, Molecular and cellular biology.

[97]  G. Hayward,et al.  Sequence-specific DNA binding of the Epstein-Barr virus nuclear antigen (EBNA-1) to clustered sites in the plasmid maintenance region , 1985, Cell.

[98]  J. Gutkind,et al.  The Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor as a therapeutic target for the treatment of Kaposi's sarcoma. , 2006, Cancer research.

[99]  C. Gélinas,et al.  Epstein-Barr virus nuclear antigen 2 trans-activates the cellular antiapoptotic bfl-1 gene by a CBF1/RBPJ kappa-dependent pathway. , 2006, Journal of virology.

[100]  J. Pagano,et al.  Up-regulation of beta-catenin by a viral oncogene correlates with inhibition of the seven in absentia homolog 1 in B lymphoma cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[101]  M. Rettig,et al.  Transcriptional coactivation of c-Jun by the KSHV-encoded LANA. , 2004, Blood.

[102]  B. Damania.  Oncogenic gamma-herpesviruses: comparison of viral proteins involved in tumorigenesis. , 2004, Nature reviews. Microbiology.

[103]  J. Gutkind,et al.  Endothelial infection with KSHV genes in vivo reveals that vGPCR initiates Kaposi's sarcomagenesis and can promote the tumorigenic potential of viral latent genes. , 2003, Cancer cell.

[104]  G. Hayward.  Initiation of angiogenic Kaposi's sarcoma lesions. , 2003, Cancer cell.

[105]  S. Howell,et al.  KSHV vFLIP binds to IKK-gamma to activate IKK. , 2003, Journal of cell science.

[106]  N. Jones,et al.  Modulation of p27(Kip1) levels by the cyclin encoded by Kaposi's sarcoma-associated herpesvirus. , 1999, The EMBO journal.

[107]  E. Kieff,et al.  Epstein-Barr virus-transforming protein latent infection membrane protein 1 activates transcription factor NF-kappaB through a pathway that includes the NF-kappaB-inducing kinase and the IkappaB kinases IKKalpha and IKKbeta. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[108]  E. Kieff,et al.  The Epstein-Barr virus oncogene product latent membrane protein 1 engages the tumor necrosis factor receptor-associated death domain protein to mediate B lymphocyte growth transformation and activate NF-kappaB. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[109]  J. Yates,et al.  Stable replication of plasmids derived from Epstein–Barr virus in various mammalian cells , 1985, Nature.